Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months % 3-5 years
Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine
Infections, Meningococcal
Phase 2
The results of study 103533 are summarised with study 103534 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided
June 2014